Survodutide is a long-acting peptide that activates both glucagon and GLP-1 receptors. The design combines appetite and glucose regulation with a glucagon-related influence on liver metabolism and energy balance. Published trials now include phase 3 weight-management studies in adults with and without type 2 diabetes, alongside a biopsy-based phase 2 study in metabolic dysfunction-associated steatohepatitis, or MASH. Together, these studies show why weight change, glucose control and liver histology need to be interpreted as distinct outcomes of the same engineered molecule. Survodutide remains investigational as of October 13, 2026. Zimmermann et al. (2022), le Roux et al. (2026), Wharton et al. (2026).
Overview
Molecular profile
The development code BI 456906 identifies survodutide. It is a single modified peptide with two receptor activities. Zimmermann and colleagues described modifications that improved resistance to enzymatic breakdown and promoted albumin binding. An attached fatty-acid group helps the peptide associate with albumin in blood, extending exposure compared with a rapidly degraded native hormone. Zimmermann et al. (2022).
Uses and research areas
The obesity programme evaluates body weight and associated metabolic outcomes. Separate phase 3 populations include adults without diabetes and adults with type 2 diabetes, whose glucose regulation, background medicines and weight responses differ. Both programmes include lifestyle counselling alongside the study intervention.
The liver programme examines MASH, a condition in which metabolic fat accumulation is accompanied by liver-cell injury and inflammation. Fibrosis is the scarring that can follow persistent injury. A biopsy can distinguish changes in disease activity from changes in scar tissue, providing a more specific assessment than liver-fat imaging alone. Sanyal et al. (2024).
Mechanism of action
GLP-1 receptor signalling enhances insulin secretion when glucose is elevated and participates in appetite regulation. Glucagon receptor signalling acts prominently in the liver, influencing glucose production, amino-acid metabolism and fat handling. Combining the receptors requires a favourable net metabolic effect: glucagon-related actions may help energy balance while the GLP-1 component supports glucose control.
Thomas and colleagues compared candidate dual agonists in receptor-expressing cells and mice. After a glucose challenge, mice given survodutide and two selected candidates had smaller blood-glucose rises than animals given the vehicle without an agonist; semaglutide provided an active comparison. The researchers also measured increases in blood FGF21, a hormone involved in metabolism, and in liver RNA for the enzyme NNMT to assess glucagon-receptor engagement. Together these responses helped select survodutide for development. The biomarkers were measured in specific preclinical systems, so the clinical weight studies still need to establish the resulting human effect. Thomas et al. (2024).
The development studies also illustrate why the phrase "balanced dual agonism" needs experimental context. Relative activity depends on the receptor system, albumin conditions and biological measurement. A receptor potency ratio cannot be read directly as a ratio of clinical benefits.
Pharmacokinetics
Survodutide's albumin-binding modification and resistance to proteolysis support prolonged exposure. Thomas and colleagues measured plasma peptide concentrations in mice after intravenous and subcutaneous administration, characterising clearance, distribution and bioavailability. Those animal measurements explain part of the development process, while the clinical trials establish that sustained subcutaneous exposure can produce human weight and glucose effects. Thomas et al. (2024).
The primary sources reviewed here do not supply a sufficiently verified human concentration–time dataset or a population-specific human half-life for an exposure illustration. A mouse curve would answer a different question from the clinical pharmacokinetics readers are most likely to seek.
Research findings
The phase 2 obesity trial and treatment completion
The 46-week dose-finding study enrolled 387 adults without diabetes, of whom 386 received study treatment. Mean weight changes under the planned-treatment primary analysis were −6.2%, −12.5%, −13.2% and −14.9% across the four active assignments, versus −2.8% with placebo. The primary modified intention-to-treat analysis used the assignment at randomisation and censored COVID-related discontinuations. An actual-treatment sensitivity analysis instead used maintenance exposure and on-treatment data. le Roux et al. (2024).
Only 233 of the 386 treated participants completed treatment. Completion was about 61% in the pooled survodutide groups and 60% with placebo, so both groups lost substantial follow-up and drug intolerance cannot explain all of it. An analysis using measurements only while participants continued treatment answers a different question from one that follows everyone assigned treatment. This distinction helps explain the larger on-treatment estimate.
Phase 3 in adults without and with diabetes
SYNCHRONIZE-1 studied 725 adults without diabetes for 76 weeks. Under the treatment-regimen estimand, mean weight changes were −12.2% and −13.0% in the two survodutide groups versus −5.4% with placebo. At least 5% weight reduction occurred in 72.6%, 71.9% and 46.3%, respectively. This analysis incorporated treatment discontinuation and other intercurrent events defined by the protocol. le Roux et al. (2026).
SYNCHRONIZE-2 enrolled 752 adults with type 2 diabetes and BMI at least 27. At 76 weeks, treatment-regimen mean weight changes were −8.2% and −9.8% versus −3.9% with placebo. From a mean baseline HbA1c of 7.4%, changes were −0.9 and −0.8 percentage points versus −0.2. The study's analysis assessed effects regardless of treatment interruption, discontinuation or use of another anti-obesity therapy. These results describe both weight and glycaemic responses in the diabetes population. Wharton et al. (2026).
The sponsor's October 2026 headline of up to 13.1% weight reduction in SYNCHRONIZE-2 uses the efficacy analysis. The published treatment-regimen result of 9.8% addresses a broader treatment experience. Retaining the estimand resolves the apparent discrepancy between those reports. Boehringer Ingelheim (2026).
Liver-biopsy outcomes in MASH
Sanyal and colleagues compared survodutide with placebo for 48 weeks in 293 treated participants with biopsy-confirmed MASH and fibrosis stages F1–F3. Investigators examined liver samples for improvement in inflammatory injury without worsening scar tissue. This primary response occurred in 47%, 62% and 43% of the survodutide groups, compared with 14% with placebo. A separate measure asked whether scarring improved by at least one stage; it occurred in 34%, 36% and 34%, compared with 22%. These measurements address different tissue changes. Improvement in inflammatory injury alone cannot establish how much scarring is reduced or how certain that reduction is. Sanyal et al. (2024).
Safety and tolerability
Gastrointestinal symptoms were common across the clinical studies. In SYNCHRONIZE-1, they affected 80.9% and 89.7% of the active groups versus 47.9% with placebo, generally with mild or moderate severity; no deaths were reported. In SYNCHRONIZE-2, the corresponding rates were 72.8%, 77.7% and 38.6%. Treatment-regimen analyses are useful partly because an effective treatment must also be tolerable enough to continue. le Roux et al. (2026), Wharton et al. (2026).
The MASH study reported nausea in 66% of survodutide recipients versus 23% with placebo, diarrhoea in 49% versus 23%, and vomiting in 41% versus 4%. Serious adverse events occurred in 8% versus 7%. The liver-disease population supplies a separate safety context from the obesity studies. Sanyal et al. (2024).
Published phase 3 results are an important development milestone, but survodutide remains an investigational product. The programme still needs longer-term outcomes and regulatory assessment for the particular indications being studied. Wharton et al. (2026), Boehringer Ingelheim (2026).
What the research means
Survodutide has established weight effects in phase 3 populations on both sides of the diabetes distinction. The liver trial adds tissue-level evidence about MASH activity, and the preclinical work supplies a receptor-based rationale for examining metabolism beyond appetite.
The practical interpretation depends on the outcome being measured. A weight percentage, HbA1c change and biopsy response represent different aspects of disease. The treatment-regimen results also differ from adherence-assuming estimates. Reading those labels together with attrition and gastrointestinal events gives a clearer account of the treatment experience than selecting the largest percentage across reports.
FAQs
Why does the headline differ from the published diabetes weight figure?
The sponsor's 13.1% headline estimates what happened under continued treatment, using the efficacy analysis. The published 9.8% result for the higher-assignment group instead includes the experience of people who interrupted or stopped treatment or used another anti-obesity therapy. These analyses answer different questions about the same trial.
How do liver activity and fibrosis endpoints differ?
MASH activity concerns inflammatory injury. Fibrosis is accumulated scar tissue. Biopsy-based activity improvement and one-stage fibrosis improvement are separate tissue outcomes.
Why is there no human exposure graph here?
Verified primary material did not supply a documented human concentration series or a population-specific half-life sufficient for that graph. Mouse measurements answer a preclinical question.
Comparisons and related reading
Mazdutide and pemvidutide use the same broad glucagon/GLP-1 receptor pairing, while retatrutide adds GIP receptor activity. Their molecular designs and clinical programmes remain distinct. Semaglutide provides a selective GLP-1 reference for understanding the added biological rationale.
References
The discovery report connects dual receptor activity, proteolytic stability, albumin association and preclinical effects.
The phase 2 obesity trial distinguishes planned and actual-treatment analyses and records attrition.
SYNCHRONIZE-1 reports treatment-regimen weight change without diabetes and gastrointestinal event rates.
SYNCHRONIZE-2 reports weight and HbA1c outcomes in a distinct diabetes population.
The MASH trial measures biopsy-defined disease activity and fibrosis as separate outcomes.
The preclinical study links receptor potency to biomarkers and mouse PK.
The sponsor identifies the estimand behind its weight headline.
Glossary
- MASH
- Metabolic dysfunction-associated steatohepatitis, involving metabolic liver fat with inflammatory injury.
- Fibrosis
- Scar tissue accumulated following sustained injury.
- FGF21
- Fibroblast growth factor-21, a metabolic protein used here as a preclinical glucagon-related biomarker.
- Proteolysis
- Enzymatic breakdown of a peptide or protein.
- Estimand
- The treatment effect and handling of treatment changes that an analysis estimates.
- Modified intention to treat
- An analysis population with stated post-randomisation inclusion criteria.